- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT02693145
Cooperative Re-Engagement Controlled Trial (CoRECT) (CoRECT)
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Methods summary: Health departments will generate an out-of-care list using HIV laboratory surveillance data; collaborating clinics will concurrently generate out-of-care lists using appointment data. The combined out-of-care list will be reconciled by the health department and clinics, and discussed at monthly case conferences. All individuals determined to be out-of care will be randomized to receive either: (1) usual linkage and engagement in care services (standard of care [SOC]); or (2) an active health department field services intervention in addition to SOC. The active intervention activities will vary among jurisdictions; however all sites will include field services to locate, contact, and provide assistance, including a same-day appointment, to access HIV medical care.
Study design: Each site will enroll 600 out-of-care HIV-infected individuals (300 per arm) during a two-year enrollment period. An out-of-care individual will be defined as: (1) a person who has received HIV medical care at a CoRECT clinic and then disengages from care; or (2) a person with newly diagnosed HIV infection who has an appointment at a CoRECT clinic, but has not linked to medical care within 90 days.
Intervention: Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Services provided as part of the intervention will vary by jurisdiction, but may include assistance with expedited medical appointments, transportation, access to community resources such as traditional case management, strengths-based case management, or financial incentives (Appendix A).
Primary outcomes: The following outcomes will be compared between out-of-care HIV-infected individuals receiving the study intervention to those receiving usual services:
- Attend 1 clinic visit within 90 days;
- Remain engaged in care, defined as 2 clinic visits at least 3 months apart within 12 months;
- Achieve viral load suppression within 12 months;
- Achieve durable viral load suppression, defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Connecticut
-
Hartford, Connecticut, Egyesült Államok, 06106
- Connecticut Department of Public Health
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02108
- Massachusetts Department of Public Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104
- Philadelphia Department of Health
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
Residents within the health department jurisdiction who have received HIV medical care at a CoRECT clinic and then disengage by either of the following definitions:
- Clinic definition: did not have a visit with a prescribing provider for 6 months.
- Health department definition: no CD4 or viral load test result reported to health department surveillance for more than 6 months.
Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days and have either:
- Received, but did not attend, an appointment at a CoRECT clinic; or
- Attended an enrollment visit but did not receive medical care at a CoRECT clinic.
Exclusion Criteria:
- Deceased
- Out of jurisdiction
- Changed providers
- Incarcerated
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Egészségügyi szolgáltatások kutatása
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Nincs beavatkozás: standard of care (SOC) arm
Individuals found to be out of HIV medical care will receive standard of care to re-engage.
This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
|
|
Kísérleti: Intervention arm
Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care.
Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
|
Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result.
ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology.
SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Attend one clinic visit
Időkeret: within 90 days of randomization
|
Patient will attend one clinical visit at CoRECT clinic to receive HIV medical care
|
within 90 days of randomization
|
Remain engaged in care
Időkeret: defined as 2 clinic visits at least 3 months apart within 12 months
|
Two or more medical visits at least 3 months apart within 12 months to demonstrate patient remains engaged in HIV medical care
|
defined as 2 clinic visits at least 3 months apart within 12 months
|
Viral load suppression
Időkeret: within 12 months
|
Does the patient achieve viral load suppression within 12 months of randomization
|
within 12 months
|
Achieve durable viral load suppression
Időkeret: defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
Achieve durable viral load suppression, defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
Együttműködők és nyomozók
Publikációk és hasznos linkek
Általános kiadványok
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.
- Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, Sansom SL, Siegal HA, Greenberg AE, Holmberg SD; Antiretroviral Treatment and Access Study Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005 Mar 4;19(4):423-31. doi: 10.1097/01.aids.0000161772.51900.eb.
- The White House Office of National AIDS Policy. National HIV/AIDS Strategy. Available at: http://www.whitehouse.gov/administration/eop/onap/nhas. Accessed: 30 January 2015.
- Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, Skarbinski J, Higa DH, Prejean J, Frazier EL, Patel R, Huang P, An Q, Song R, Tang T, Valleroy LA. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1113-7.
- Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JH. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015 Apr;175(4):588-96. doi: 10.1001/jamainternmed.2014.8180.
- Gardner LI, Marks G, Craw JA, Wilson TE, Drainoni ML, Moore RD, Mugavero MJ, Rodriguez AE, Bradley-Springer LA, Holman S, Keruly JC, Sullivan M, Skolnik PR, Malitz F, Metsch LR, Raper JL, Giordano TP; Retention in Care Study Group. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012 Oct;55(8):1124-34. doi: 10.1093/cid/cis623. Epub 2012 Jul 24.
- Gardner LI, Giordano TP, Marks G, Wilson TE, Craw JA, Drainoni ML, Keruly JC, Rodriguez AE, Malitz F, Moore RD, Bradley-Springer LA, Holman S, Rose CE, Girde S, Sullivan M, Metsch LR, Saag M, Mugavero MJ; Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. Clin Infect Dis. 2014 Sep 1;59(5):725-34. doi: 10.1093/cid/ciu357. Epub 2014 May 15.
- Dombrowski JC. Testing, Linkage and Retention in Care: Getting Control of the Cascade in Seattle. National Summit on HIV and Viral Hepatitis Diagnosis, Prevention, and Access to Care, Washington, DC, November 26-8, 2012.
- Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013 Sep 10;27(14):2271-9. doi: 10.1097/QAD.0b013e328362fdde.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- RNS vírusfertőzések
- Vírusos betegségek
- Fertőzések
- Vérrel terjedő fertőzések
- Fertőző betegségek
- Szexuális úton terjedő betegségek, vírusos
- Szexuális úton terjedő betegségek
- Lentivírus fertőzések
- Retroviridae fertőzések
- Immunhiányos szindrómák
- Immunrendszeri betegségek
- Lassú vírusos betegségek
- HIV fertőzések
- Szerzett immunhiányos szindróma
- Fertőzésgátló szerek
- Vírusellenes szerek
- Retrovirális szerek
Egyéb vizsgálati azonosító számok
- FOA PS14-001
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Humán immunhiány vírus
-
Merck Sharp & Dohme LLCBefejezveHuman Immunodeficiency Virus-1 (HIV-1)
-
EMD SeronoBefejezveHuman Immunodeficiency Virus Associated Adipose Redistribution SyndromeEgyesült Államok, Kanada
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Allergy and Infectious Diseases (NIAID)BefejezveHIV fertőzések | Betegségátvitel, függőleges | Vertical Human Immunodeficiency Virus TransmissionEgyesült Államok, Dél-Afrika, Argentína, Brazília, Puerto Rico
-
AlexionAchillion, a wholly owned subsidiary of AlexionBefejezveHuman Immunodeficiency Virus (HIV)-1 fertőzésEgyesült Államok, Spanyolország, Németország, Dominikai Köztársaság
-
University of North Carolina, Chapel HillAstellas Pharma US, Inc.Befejezve
-
EMD SeronoBefejezveHumán immunhiányos vírusfertőzések | Human Immunodeficiency Virus-asssociated Adipose Redistribution Syndrome (HARS)
-
Guangzhou University of Traditional Chinese MedicineUniversity of HoustonToborzásXiao Chai Hu Tang | Irinotekán okozta hasmenésKína
-
Janssen PharmaceuticaVisszavontHuman Immunodeficiency Virus 1 Type (HIV-1) fertőzés
-
EMD SeronoBefejezveHumán immunhiányos vírusfertőzések | Human Immunodeficiency Virus-asssociated Adipose Redistribution Syndrome (HARS)
-
Gilead SciencesMegszűntHuman Immunodeficiency Virus 1 Type (HIV-1) fertőzésEgyesült Államok
Klinikai vizsgálatok a Anti-Retroviral Treatment and Access to Services (ARTAS)
-
University of Alabama at BirminghamJohns Hopkins University; Birmingham AIDS Outreach; AIDS UnitedBefejezveHIV fertőzés | A HIV-gondozás elvesztése a nyomon követésig